Three-dimensional controlled interstitial hyperthermia combined with radiotherapy for locally advanced prostate carcinoma - A feasibility study

被引:24
作者
Van Vulpen, M
Raaymakers, BW
Lagendijk, JJW
Crezee, J
De Leeuw, AAC
Van Moorselaar, JRA
Ligtvoet, CM
Battermann, JJ
机构
[1] Univ Utrecht, Med Ctr, Dept Radiat Oncol, NL-3548 CX Utrecht, Netherlands
[2] Univ Utrecht, Med Ctr, Dept Urol, NL-3548 CX Utrecht, Netherlands
[3] Univ Utrecht, Med Ctr, Dept Biomed Engn, NL-3548 CX Utrecht, Netherlands
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2002年 / 53卷 / 01期
关键词
prostate carcinoma; interstitial hyperthermia; thermometry; perfusion; radiotherapy;
D O I
10.1016/S0360-3016(01)02828-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To perform a feasibility study of three-dimensional spatially controlled interstitial hyperthermia for locally advanced prostate cancer. Methods and Materials: Twelve patients with prostate cancer (T3NxM0) were treated with conventional external beam radiotherapy and one interstitial hyperthermia treatment. Hyperthermia was delivered with the 27-MHz multielectrode current source (MECS) interstitial hyperthermia technique on an outpatient basis. Guided by transrectal ultrasonography, 12 catheters (range 7-16) were placed in the prostate through a template. Two electrodes per probe were inserted. Thermometry (average 100 sensors) was performed from within the probes for online temperature control. Additional thermometry was done in the prostate, rectum, urethra, and bladder. Reconstruction was done by sonography. Prostate perfusion was estimated from the thermal decay at the end of treatment. The full three-dimensional temperature distribution was calculated. Results: No toxicities greater than Grade 2 were recorded. A learning curve for implantation, position verification, reconstruction, and temperature simulation was experienced. Perfusion was 47 mL/100 g/min (range 30-65). The average measured temperature was T-90 (90% of the prostate reached a temperature of at least:) 39.9degreesC and T-50 44.1degreesC. The average calculated temperatures were lower: T-90, 39.4degreesC and T-50, 41.8degreesC, because the entire prostate was taken into account. The tumor temperatures were T-90, 40.7degreesC and T-50, 43.0degreesC. The bladder and rectal temperatures were below the safety limits. Conclusion: Multielectrode-current-source interstitial hyperthermia is technically feasible and well tolerated. It was not possible to achieve the goal temperature of 42-43degreesC because of high perfusion and implantation limitations. (C) 2002 Elsevier Science Inc.
引用
收藏
页码:116 / 126
页数:11
相关论文
共 47 条
[1]  
Algan Ö, 2000, CANCER, V89, P399, DOI 10.1002/1097-0142(20000715)89:2<399::AID-CNCR27>3.0.CO
[2]  
2-4
[3]   Combined external beam irradiation and external regional hyperthermia for locally advanced adenocarcinoma of the prostate [J].
Anscher, MS ;
Samulski, TV ;
Dodge, R ;
Prosnitz, LR ;
Dewhirst, MW .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 37 (05) :1059-1065
[4]   I-125 implantation for localized prostate cancer: the Utrecht University experience [J].
Battermann, JJ .
RADIOTHERAPY AND ONCOLOGY, 2000, 57 (03) :269-272
[5]  
Borre M, 1997, CANCER, V80, P917
[6]   EVALUATION OF EQUIPMENT FOR HYPERTHERMIC TREATMENT OF CANCER [J].
CORRY, PM ;
JABBOURY, K ;
KONG, JS ;
ARMOUR, EP ;
MCCRAW, FJ ;
LEDUC, T .
INTERNATIONAL JOURNAL OF HYPERTHERMIA, 1988, 4 (01) :53-74
[7]   Implications of using thermocouple thermometry in 27 MHz capacitively coupled interstitial hyperthermia [J].
Crezee, J ;
vanderKoijk, JF ;
Kaatee, RSJP ;
Lagendijk, JJW .
PHYSICS IN MEDICINE AND BIOLOGY, 1997, 42 (04) :637-650
[8]   A 3-D SAR model for current source interstitial hyperthermia [J].
deBree, J ;
VanderKoijk, JF ;
Lagendijk, JJW .
IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING, 1996, 43 (10) :1038-1045
[9]   TEMPERATURE AND SAR MEASUREMENTS IN DEEP-BODY HYPERTHERMIA WITH THERMOCOUPLE THERMOMETRY [J].
DELEEUW, AAC ;
CREZEE, J ;
LAGENDIJK, JJW .
INTERNATIONAL JOURNAL OF HYPERTHERMIA, 1993, 9 (05) :685-697
[10]  
DEVONEC M, 1993, EUR UROL, V23, P63